Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): an open-label, randomised, phase 3 factorial trial

Denham, James W.; Joseph, David; Lamb, David; Spry, Nigel; Duchesne, Gillian; Matthews, John; Atkinson, Callum; Tai, Keen‐Hun; Christie, David; Kenny, Liz; Turner, Sandra; Gogna, Nirdosh Kumar; Diamond, Terry; Delahunt, Brett; Oldmeadow, Christopher; Attia, John; Steigler, Allison

doi:10.1016/s1470-2045(14)70328-6

Cited by 125 publications

(80 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In our main endpoints analyses we identified an interaction between the use of Z and GS of the primary tumour for all distant progression related endpoints [10]. Our first step in this analysis therefore was to determine whether this interaction influenced our potential LP surrogate endpoints.…”

Section: Analysesmentioning

confidence: 99%

Radiation dose escalation or longer androgen suppression for locally advanced prostate cancer? Data from the TROG 03.04 RADAR trial

Denham

Steigler

Joseph

et al. 2015

Radiotherapy and Oncology

Self Cite

View full text Add to dashboard Cite

Section: Analysesmentioning

confidence: 99%

Radiation dose escalation or longer androgen suppression for locally advanced prostate cancer? Data from the TROG 03.04 RADAR trial

Denham

Steigler

Joseph

et al. 2015

Radiotherapy and Oncology

Self Cite

View full text Add to dashboard Cite

“…These patients were treated as part of the Trans-Tasman Radiation Oncology Group (TROG) 03.04 Randomized Androgen Deprivation and Radiotherapy (RADAR) trial [14,15]. The patient criteria and treatment methodology for the RADAR trial have previously been detailed [14,15].…”

Section: Patient Datamentioning

confidence: 99%

Prostate external beam radiotherapy combined with high-dose-rate brachytherapy: dose-volume parameters from deformably-registered plans correlate with late gastrointestinal complications

et al. 2016

View full text Add to dashboard Cite

Background: Derivation of dose-volume correlated with toxicity for multi-modal treatments can be difficult due to the perceived need for voxel-by-voxel dose accumulation. With data available for a single-institution cohort with long follow-up, an investigation was undertaken into rectal dose-volume effects for gastrointestinal toxicities after deformably-registering each phase of a combined external beam radiotherapy (EBRT)/high-dose-rate (HDR) brachytherapy prostate treatment.

show abstract

“…The standard of care for LAPC has been continuously refined with contributions from multiple randomized clinical trials over the last ~30 11 the EORTC 22961 trial, 12 and the TROG 03.04 trial 13 (see Table 1). These will be briefly reviewed here.…”

Section: Origins Of the Standard Of Care For Locally Advanced Prostatmentioning

confidence: 99%

Recent Developments in Androgen Deprivation Therapy for Locally Advanced Prostate Cancer

Bader¹,

Černe²,

McGuire³

2014

Oncology &Amp; Hematology Review (US)

View full text Add to dashboard Cite

133Prostate cancer is the most commonly diagnosed noncutaneous cancer and second leading cause of cancer mortality in American men. The lifetime risk for prostate cancer is estimated at one in six; 30,000 men die of the disease annually in the US.1 Prostate cancer is driven by the hormonally responsive transcription factor androgen receptor (AR) and the majority of prostate cancers are detected via serum level increase of the AR target gene prostate-specific antigen (PSA). Localized and low-risk prostate cancer is actively monitored or treated via radical prostatectomy (RP), brachytherapy, or external beam radiation therapy (EBRT). KeywordsLocally advanced prostate cancer (LAPC), androgen deprivation therapy (ADT), androgen receptor (AR), dose-escalation, external beam radiotherapy (EBRT), conformal radiotherapy (CRT), continuous and intermittent ADT (CAD, IAD), prostate specific antigen (PSA), castration resistant prostate cancer (CRPC), radiotherapy synergy, luteinizing hormone-releasing hormone (LHRH) analog, androgen receptor antagonist, anti-androgen, CYP17 inhibitor, molecular and metabolic markers, biomarkers

show abstract

Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): an open-label, randomised, phase 3 factorial trial

Cited by 125 publications

References 40 publications

Radiation dose escalation or longer androgen suppression for locally advanced prostate cancer? Data from the TROG 03.04 RADAR trial

Radiation dose escalation or longer androgen suppression for locally advanced prostate cancer? Data from the TROG 03.04 RADAR trial

Prostate external beam radiotherapy combined with high-dose-rate brachytherapy: dose-volume parameters from deformably-registered plans correlate with late gastrointestinal complications

Recent Developments in Androgen Deprivation Therapy for Locally Advanced Prostate Cancer

Contact Info

Product

Resources

About